There is a huge difference between saying what you want to do and actually achieving it in a commercial sense.
From what I see, they have some sort of sample testing machine that can be configured in multiple ways. Obviously, they would be looking for financial backing at this stage (either private or public). To that end it is probably a good move to mention Tuberculosis as a candidate test.
If they are going to produce a TB test they will need to measure something. What are they going to measure? They can perhaps look for the TB organism itself in samples (blood, urine, whatever). If they were able to do that then it would be a test for ACTIVE TB. Alternatively, they can look for an antibody response (like TST). That would detect latent TB but would suffer all the same specificity problems of TST. Perhaps they could look for a T-cell response via IFg - if they did that then they would have to licence from the patent holder - CST.
Frankly, I doubt they will be able to do it. If by some chance they are, then we could expect to see their product on the market in say 10 or 12 years.
- Forums
- ASX - By Stock
- CST
- mycrolab tb testing
mycrolab tb testing, page-7
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CST (ASX) to my watchlist